Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Novavax Down Second Straight Day On Concerns About Delays

Published 05/11/2021, 01:05 PM
Updated 05/11/2021, 01:10 PM
©  Reuters
PFE
-
NVAX
-
AZN
-
MRNA
-
BNTX
-

By Dhirendra Tripathi

Investing.com – Novavax (NASDAQ:NVAX) extended losses for the second consecutive day, plunging 12% in Tuesday’s trade a day after the vaccine maker said it is pushing back its timetable for seeking regulatory approvals for its Covid-19 shot.

The company said it intended to apply for permissions in the U.S, the U.K. and Europe in the next quarter.

Cumulatively, Novavax share price is now down by more than half of its year’s high of $331.

Market makers are puzzled by the continuing delay at the company’s end at a time when the likes of Pfizer (NYSE:PFE)-BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) have supplied millions of doses in the U.S., and AstraZeneca (NASDAQ:AZN) has done so in Europe and India.

A Washington Post report Monday said the company delayed plans to seek emergency use authorization.

The Gaithersburg-based vaccine developer is yet to supply a single dose even as it has manufacturing agreements with India’s Serum Institute, Japan’s Takeda and South Korea’s SK Bioscience to make the shots.

 

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.